The genetic engineering industry in the Nordics is a vibrant and innovative sector, focusing on the manipulation of living organisms to develop new technologies and therapies. Companies range from startups harnessing CRISPR technology to established firms improving agricultural outcomes and human healthcare. The emphasis on research and development is strong, with a robust collaboration between universities and the private sector. This sector is set for substantial growth, driven by advancements in genomics and biotech. Moreover, Nordic countries invest heavily in health and science, propelling initiatives that expand access to personalized medicine and sustainable solutions.


Investors in the Nordic genetic engineering space include a mix of venture capital firms and corporate entities, with representation from Denmark, Sweden, and Finland. Established from 1994 to 2018, these investors exhibit varying investment sizes and strategies, with deal counts in 2024 reaching up to 45 for some. Companies like Novo Holdings and Almi actively support innovative startups in biotechnology, providing crucial funding for groundbreaking projects. With most firms operating on a multi-million scale, the Nordic ecosystem is highly supportive of ambitious scientific endeavors.


Top 18 Genetic Engineering Investors in the Nordics


1. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, they have been involved in significant transactions within the genetic engineering sector, including a $100 million investment in Metagenomi, a gene editing startup, in January 2023. They also participated in a $175 million Series B funding round for Metagenomi in January 2022, highlighting their commitment to advancing gene editing technologies. Other relevant investments include a $94 million Series B round for Verve Therapeutics and a $65 million Series A-1 financing for iECURE, both of which are engaged in innovative therapeutic approaches that may involve genetic engineering. These transactions underscore Novo Holdings' active role in the genetic engineering landscape.


2. Almi

  • Website: almi.se
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 201-500
  • Number of deals in 2024: 7
  • LinkedIn: almi-ab

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden, with the goal of enhancing their growth and competitiveness. Almi has been involved in several notable transactions in the biotechnology and genetic engineering sectors. For instance, they invested in Strike Pharma, which is developing a new efficient cancer treatment, raising close to 10 million Swedish crowns to fund this innovative technology. Additionally, Almi has supported Fluicell, a company that operates in the biotech space, and has made investments in other firms like Countagen and Beactica Therapeutics AB, which are also relevant to the genetic engineering field. These investments highlight Almi's active role in fostering advancements in biotechnology and genetic engineering.


3. HealthCap

  • Website: healthcap.eu
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1996
  • Headcount: 11-50
  • Number of deals in 2024: 5
  • LinkedIn: healthcap

HealthCap is a venture capital firm based in Stockholm, Sweden, founded in 1996. The firm specializes in the life sciences sector, focusing on innovative companies that are developing breakthrough therapies for diseases with high unmet medical needs. HealthCap has a strong track record of investing in biotechnology firms, including notable transactions in the genetic engineering field. For instance, they participated in a $36M Series B financing round for GenSight Biologics, which is advancing gene therapy approaches for treating genetic disorders. Additionally, HealthCap was involved in funding Aro Biotherapeutics, which is developing Centyrin-targeted genetic medicines, and Rampart Bioscience, which is working on DNA-based medicines. These investments highlight HealthCap's commitment to supporting advancements in genetic engineering and related biotechnologies.


4. Business Finland

  • Website: businessfinland.fi
  • Type: Corporate
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2018
  • Headcount: 501-1000
  • Number of deals in 2024: 26
  • LinkedIn: business-finland

Business Finland is a public entity based in Helsinki, Uusimaa, Finland, founded in 2018. It supports Finnish companies in their growth and internationalization efforts by offering funding, consulting services, and market opportunities. The organization plays a crucial role in promoting trade, tourism, and foreign investment in Finland. In the context of genetic engineering, Business Finland has been involved in several significant transactions, including investments in Aurealis Pharma, which focuses on diabetic foot ulcers and oncology, and TILT Biotherapeutics, which is advancing cancer immunotherapies. Their funding has included both equity and grants, with notable amounts directed towards companies developing innovative therapies that leverage genetic engineering techniques.


5. Industrifonden

  • Website: industrifonden.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1979
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: industrifonden

Industrifonden is a venture capital fund based in Stockholm, Sweden, founded in 1979. The fund specializes in investing in early-stage companies, particularly in the fields of Deep Tech, Life Science, and Transformative Tech. Industrifonden provides financial support and strategic guidance to startups, helping them scale their innovative solutions. Notably, they have participated in significant funding rounds for companies such as Asgard Therapeutics, which raised over $32 million in Series A funding in 2024, and Cellevate, which secured 39 million SEK in Seed Financing in 2023. Their involvement with Oncopeptides, a company focused on developing treatments for multiple myeloma, further highlights their commitment to the Life Science sector. Through these investments, Industrifonden aims to create long-term value by partnering with passionate founders and supporting groundbreaking advancements in biotechnology and genetic engineering.


6. Lundbeckfonden / Lundbeck Foundation

  • Website: lundbeckfonden.com
  • Type: Venture Capital
  • Headquarters: Copenhagen, Denmark
  • Founded year: 1954
  • Headcount: 11-50
  • Number of deals in 2024: 1
  • LinkedIn: lundbeckfonden

Lundbeckfonden / Lundbeck Foundation is a not-for-profit organization based in Copenhagen, Denmark, founded in 1954. It is dedicated to funding health science research, particularly in brain-related studies, and provides various grants and scholarships to researchers and academic institutions in Denmark. The foundation plays a crucial role in supporting the translation and commercialization of groundbreaking science. Notably, Lundbeckfonden has been involved in significant transactions in the genetic engineering sector, including co-leading a $50 million Series A financing in SNIPR Biome, a company focused on CRISPR technology and microbiome applications. This investment aims to further develop the company's CRISPR technology platform and its clinical programs. Additionally, Lundbeckfonden has participated in funding rounds for companies like LEXEO Therapeutics, which is engaged in genetic research related to rare cardiovascular diseases and Alzheimer's disease. These activities highlight Lundbeckfonden's commitment to advancing genetic engineering and related health sciences.


7. Flerie

  • Website: flerie.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2011
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: flerie

Flerie is a Stockholm-based venture capital firm founded in 2011, specializing in life sciences with a focus on biotech and pharmaceutical investments. The firm supports a portfolio of over 30 companies by providing resources and expertise to navigate drug development challenges. Flerie's investment strategy is primarily focused on Europe, Israel, and the US, aiming to create long-term value through strategic investments. Notably, Flerie has participated in significant funding rounds for companies involved in genetic engineering and biotechnology. For instance, they led a funding round for Prokarium, which is developing synthetic biology techniques for vaccines, and have invested in Amarna Therapeutics, which is working on advancing its SVac platform for clinical studies. Their involvement in these transactions highlights their commitment to supporting innovative solutions in the genetic engineering space.


8. Novo Nordisk

  • Website: novonordisk.com
  • Type: Corporate
  • Headquarters: Denmark
  • Founded year: 1923
  • Headcount: 10001+
  • Number of deals in 2024: 4
  • LinkedIn: novo-nordisk

Novo Nordisk A/S is a multinational pharmaceutical company based in Denmark, founded in 1923, specializing in diabetes care and treatments for other chronic diseases. The company develops and manufactures a range of medications, including semaglutide and various insulin products, aimed at improving patient health. In recent years, Novo Nordisk has expanded its investment portfolio to include companies involved in genetic engineering and advanced biotechnologies. Notable transactions include their participation in a $401 million Series D funding round for ElevateBio, which focuses on genetic engineering technologies, and their involvement in Unum Therapeutics' Series B financing, aimed at advancing their Antibody-Coupled T-cell Receptor (ACTR) technology platform. Additionally, Novo Nordisk has invested in Affimed Therapeutics, which is developing therapeutic antibody technologies, further showcasing their engagement in the genetic engineering space. These investments highlight Novo Nordisk's strategic interest in innovative biotechnologies that align with their mission to improve patient health.


9. Sunstone Life Science Ventures


Sunstone Life Science Ventures is a venture capital firm based in Copenhagen, Denmark, founded in 2007. The firm specializes in investments in early-stage life science companies, focusing on developing and expanding innovations in therapeutics, medical technology, and diagnostics. Sunstone provides funding and business development support to help its portfolio companies navigate the path from research to market. Notable transactions include a $64 million investment in Galecto, which is advancing therapies for idiopathic pulmonary fibrosis, and participation in a €57 million Series A financing for Kynexis, a biotech company focused on precision therapeutics for brain diseases. These investments highlight Sunstone's engagement in sectors that are closely related to genetic engineering, particularly in the context of developing novel therapies and precision medicine.


10. Hadean Ventures

  • Website: hadeanventures.com
  • Type: Venture Capital
  • Headquarters: Oslo, Oslo, Norway
  • Founded year: 2014
  • Headcount: 11-50
  • Number of deals in 2024: 1
  • LinkedIn: hadean-ventures

Hadean Ventures is a venture capital firm based in Oslo, Norway, founded in 2014. The firm specializes in the life sciences sector, managing approximately EUR 230 million in assets. Hadean Ventures focuses on investing in healthcare startups to support the development of innovative medical solutions. Among their notable transactions, they participated in the Series A financing round for Ribbon Biolabs, which raised EUR 18 million, and the Series B round for ARTHEx Biotech, which raised $46.36 million. Additionally, they were involved in the first-round financing for Complement Therapeutics, which raised €72 million for their gene therapy aimed at treating geographic atrophy. These investments highlight Hadean Ventures' active role in the genetic engineering space, particularly in supporting companies that are developing advanced therapeutic solutions.


11. Chalmers Ventures


Chalmers Ventures is a venture builder and tech investor based in Sweden, founded in 2015. They focus on deep tech innovations and support researchers and entrepreneurs in commercializing their technology through various programs that provide business guidance, financing, and community networking. In 2024, they were involved in several notable transactions, including a Pre-Seed investment in Galaxy Biosolutions, which raised $18,159, and a Seed investment in LanteRNA, which raised $517,397. LanteRNA has been a recurring investment for Chalmers Ventures, with multiple funding rounds since 2021, indicating a strong commitment to supporting advancements in RNA-based therapies. Additionally, they invested in Alpha Therapy Solution, which raised $787,354 in a Seed round, further emphasizing their focus on innovative solutions in the biotech and genetic engineering sectors.


12. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent investment firm based in Stockholm, Sweden, specializing in private equity, infrastructure, real estate, growth equity, and venture capital. Founded in 1994, EQT serves institutional investors by providing expertise in managing diverse investment portfolios across multiple sectors and geographies. Notably, EQT has made significant strides in the genetic engineering space, particularly through its acquisition of Aldevron, a key player in the supply of plasmid DNA for gene therapies, which was announced on July 31, 2019. This strategic acquisition highlights EQT's commitment to investing in innovative biotech solutions. Additionally, EQT has participated in funding rounds for companies like Xilis, which raised $19 million in Series A funding in July 2022, and HyTest, which secured an undisclosed amount in a venture round in September 2018. These transactions underscore EQT's active role in the life sciences and genetic engineering sectors, making them a noteworthy investor in this field.


13. Eir Ventures

  • Website: eirventures.eu
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2020
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: eir-ventures

Eir Ventures is a venture capital firm based in Stockholm, Sweden, founded in 2020. Specializing in the life sciences sector, Eir Ventures provides funding and support to innovative companies focused on developing new medical therapies. The firm aims to address unmet medical needs and enhance patient care through strategic investments. Notable transactions include leading a $31M Series A funding round for Scenic Biotech, which is focused on advancing its pipeline and development stage, and participating in a financing round for Strike Pharma, which is accelerating the development of its first candidate for clinical trials. These investments highlight Eir Ventures' commitment to supporting companies that may utilize genetic engineering in their therapeutic approaches.


14. Karolinska Development


Karolinska Development is a venture capital firm based in Solna, Stockholm, Sweden, founded in 2003. The firm specializes in the life sciences sector, focusing on investing in innovative pharmaceutical and medtech companies. They provide portfolio management and research support to their investments. Notably, Karolinska Development has participated in significant funding rounds for companies such as Aprea, which raised $56,592,455 in a Series C round in 2018, and Pretzel Therapeutics, which secured $72,500,000 in a Series A round in 2022. These transactions highlight their commitment to supporting advancements in life sciences, including genetic engineering. Additionally, their involvement with BOOST Pharma and ProNoxis in venture rounds indicates a continued interest in innovative healthcare solutions, further aligning them with the genetic engineering sector.


15. Investinor

  • Website: investinor.no
  • Type: Venture Capital
  • Headquarters: Trondheim, Trøndelag, Norway
  • Founded year: 2008
  • Headcount: 11-50
  • Number of deals in 2024: 4
  • LinkedIn: investinor

Investinor AS is a venture capital investment company based in Trondheim, Trøndelag, Norway, founded in 2008. The firm specializes in providing funding to promising startups and companies, helping them grow and achieve market leadership. Investinor collaborates with entrepreneurs and other investors, managing state interests in seed and venture funds. Among their notable transactions, Investinor has invested in APIM Therapeutics, which raised $3,011,750 in a venture round in December 2017, focusing on therapeutic solutions. They also participated in the seed round for Hemispherian, which raised $400,000 in January 2021, and have a history of investments in companies like Cryogenetics and PLUVIA AS, indicating their engagement in sectors that may intersect with genetic engineering and biotechnology.


16. Innovestor

  • Website: innovestorgroup.com
  • Type: Venture Capital
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2014
  • Headcount: 11-50
  • Number of deals in 2024: 12
  • LinkedIn: innovestor

Innovestor is an investment management company based in Helsinki, Uusimaa, Finland, specializing in venture capital, real estate, and energy storage. Founded in 2014, Innovestor focuses on providing funding and support to early-stage startups and corporations, particularly in technology and life sciences. Their services encompass investment advice, corporate venturing, and participation in accelerator programs. Notably, Innovestor has been involved in several significant transactions within the life sciences sector, including a Series A investment of over $20 million in Neumirna Therapeutics and a similar investment in Tribune Therapeutics. They also participated in a €28 million Series A financing round for Teitur Trophics, a biotech company advancing drug candidates into clinical development. Furthermore, Innovestor led a €1.2 million seed funding round for Brinter, a bioprinting startup, highlighting their active role in supporting innovative companies in the genetic engineering and biotechnology space.


17. Voima Ventures

  • Website: voimaventures.com
  • Type: Venture Capital
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2019
  • Headcount: 11-50
  • Number of deals in 2024: 11
  • LinkedIn: voima-ventures

Voima Ventures is a venture capital firm based in Helsinki, Finland, founded in 2019. The firm specializes in funding early-stage science-based innovations and deep tech ventures, with a strong emphasis on life sciences and advanced manufacturing. Voima Ventures has been actively investing in the Nordic and Baltic regions, providing capital and expertise to help startups scale their solutions for global challenges. Notably, they have participated in several seed funding rounds for companies such as Avenue Biosciences, which raised $2.5 million in October 2024, and StemSight, which raised over $2.3 million in February 2025. Additionally, they have invested in Finnadvance, a Finnish biotechnology startup, which has received multiple rounds of seed financing, indicating their ongoing support for ventures that may be involved in genetic engineering and related fields.


18. Seed Capital Denmark

  • Website: seedcapital.dk
  • Type: Venture Capital
  • Headquarters: Frederiksberg, Frederiksberg, Denmark
  • Founded year: 2004
  • Headcount: 1-10
  • Number of deals in 2024: 5
  • LinkedIn: seed-capital-denmark

Seed Capital Denmark is a venture capital firm based in Frederiksberg, Denmark, founded in 2004. The firm specializes in providing seed funding and advisory services to technology startups, with a focus on sectors such as SaaS and Fintech. However, they have also invested in biotechnology companies, demonstrating their interest in the life sciences sector. Notable transactions include Galecto, which raised over $6 million in a Series B round, and EmbryoTrans Biotech, which secured funding in a venture round. Additionally, they have invested in Oncology Venture, a company focused on drug development, further showcasing their engagement in the biotech and potentially genetic engineering space. This diverse investment strategy supports their portfolio companies from seed stage to exit, indicating a robust approach to nurturing innovative startups.



Genetic Engineering Insights: Key Investors in the Nordics


InvestorHeadquarterSizeFoundedDeals 2024
Novo HoldingsHellerup, Denmark51-200199945
AlmiStockholm, Stockholm, Sweden201-50019947
HealthCapStockholm, Stockholm, Sweden11-5019965
Business FinlandHelsinki, Uusimaa, Finland501-1000201826
IndustrifondenStockholm, Stockholm, Sweden11-5019799
Lundbeckfonden / Lundbeck FoundationCopenhagen, Denmark11-5019541
FlerieStockholm, Stockholm, Sweden1-1020112
Novo NordiskDenmark10001+19234
Sunstone Life Science VenturesCopenhagen, Denmark1-1020071
Hadean VenturesOslo, Oslo, Norway11-5020141
Chalmers VenturesSweden11-50201526
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
Eir VenturesStockholm, Stockholm, Sweden1-1020202
Karolinska DevelopmentSolna, Stockholm, Sweden1-1020033
InvestinorTrondheim, Trøndelag, Norway11-5020084
InnovestorHelsinki, Uusimaa, Finland11-50201412
Voima VenturesHelsinki, Uusimaa, Finland11-50201911
Seed Capital DenmarkFrederiksberg, Frederiksberg, Denmark1-1020045


Want to find more investors focusing on the genetic engineering industry?

If you want to find more investors that are active in the genetic engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!